AstraZeneca plc (AZN) Receives Buy Rating from Bryan, Garnier & Co
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating restated by Bryan, Garnier & Co in a report released on Monday. They presently have a GBX 5,220 ($63.62) price objective on the biopharmaceutical company’s stock. Bryan, Garnier & Co’s price objective points to a potential upside of 4.94% from the stock’s current price.
Other equities analysts have also issued reports about the stock. Deutsche Bank AG restated a “buy” rating and set a GBX 5,600 ($68.25) target price on shares of AstraZeneca plc in a research report on Thursday, June 30th. Citigroup Inc. restated a “buy” rating on shares of AstraZeneca plc in a research report on Thursday, June 23rd. Societe Generale restated a “buy” rating and set a GBX 6,900 ($84.10) target price on shares of AstraZeneca plc in a research report on Friday, June 24th. Berenberg Bank raised their target price on shares of AstraZeneca plc from GBX 4,950 ($60.33) to GBX 5,400 ($65.81) and gave the stock a “buy” rating in a research report on Tuesday, July 12th. Finally, BNP Paribas set a GBX 5,300 ($64.59) target price on shares of AstraZeneca plc and gave the stock a “buy” rating in a research report on Tuesday, August 2nd. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. AstraZeneca plc currently has a consensus rating of “Hold” and a consensus target price of GBX 4,960.13 ($60.45).
AstraZeneca plc (LON:AZN) traded up 0.56% during trading on Monday, reaching GBX 4974.50. 4,597,390 shares of the company’s stock were exchanged. The firm’s market capitalization is GBX 62.93 billion. The stock has a 50-day moving average price of GBX 4,994.82 and a 200 day moving average price of GBX 4,488.47. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,505.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/astrazeneca-plc-azn-receives-buy-rating-from-bryan-garnier-co.html
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.